Title for Episode VIII of world’s famous saga ‘Star Wars’ revealedSociety & Culture January 23, 21:19
Russia’s chief negotiator: Astana format gives hope for new level in negotiating processRussian Politics & Diplomacy January 23, 20:52
Astana talks focusing on mechanism of Syria ceasefire observance — oppositionWorld January 23, 20:23
Russia and Turkey hit Islamic State targets near al-Bab in Aleppo provinceWorld January 23, 20:06
Russia’s 4th Yasen-class submarine completes hydraulic testsMilitary & Defense January 23, 18:56
Arctic airport in search for investorsBusiness & Economy January 23, 18:50
Rosneft begins Arctic shelf’s seismological exploration from 2017Business & Economy January 23, 18:38
Tesla takes the lead in sales of electric cars in Russia in 2016Business & Economy January 23, 18:18
Politician says European-style reforms to degrade Ukraine’s economyWorld January 23, 18:16
SINGAPORE, July 3, 2013 /PRNewswire/ -- NeuroAiD, a stroke treatment based on Traditional Medicine, increases the odds of achieving a better functional outcome, according to research published online in the journal Stroke.
The CHIMES study is an academic international double-blind placebo-controlled clinical trial which included 1100 patients from several countries who had suffered an ischemic stroke of intermediate severity within 72 hours, treated and monitored for 3 months. Researchers found that patients who were taking NeuroAiD at acute stage had an 11 % increase in the odds of achieving independence in function and being able to perform daily activities at the end of three months. This effect was even greater when NeuroAiD was started beyond 48 hours after stroke onset, with an increase of 39%.
The odds ratio was the highest among recently completed stroke trials of neuroprotective agents. The benefit observed is clinically relevant and might have reached statistical significance with a larger sample size. In addition the study confirmed the excellent safety profile of NeuroAiD. Stroke survivors who were on NeuroAiD had fewer adverse events than those in the control group. Further studies will likely look into the benefits of longer duration of treatment.
Prof Christopher Chen, neurologist at the National University of Singapore and the principal investigator of the CHIMES study, said the results looked very promising and suggested that the effectiveness of such herbal supplements could have a great impact on stroke management. "I think one thing which is very clear is that NeuroAiD is safe in acute stroke. A previous meta-analysis suggested that NeuroAiD is efficacious and safe in the chronic stage of stroke. Now the Chimes study has provided us with much more reliable data about the safety and efficacy of NeuroAiD in acute stroke. I think the CHIMES results are not only a step forward, but also a major achievement."
Each year, 20 million people suffer from the devastating disease. However, there are only a few effective, generally accepted and specific treatments available. Therefore, there is an increasing need for multi-modal therapies to help more patients recover quickly and effectively from stroke. Moleac, a Singapore based bio-pharma company, developed NeuroAiD to meet this need.